AU2020408179B2 - Compounds for treatment of eye diseases associated with excessive vascularisation - Google Patents

Compounds for treatment of eye diseases associated with excessive vascularisation Download PDF

Info

Publication number
AU2020408179B2
AU2020408179B2 AU2020408179A AU2020408179A AU2020408179B2 AU 2020408179 B2 AU2020408179 B2 AU 2020408179B2 AU 2020408179 A AU2020408179 A AU 2020408179A AU 2020408179 A AU2020408179 A AU 2020408179A AU 2020408179 B2 AU2020408179 B2 AU 2020408179B2
Authority
AU
Australia
Prior art keywords
neovascularisation
eye
use according
chloro
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020408179A
Other languages
English (en)
Other versions
AU2020408179A1 (en
Inventor
Helena ERIKSSON
Joel Kaye
Marie TÖRNGREN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Active Biotech AB
Original Assignee
Active Biotech AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Active Biotech AB filed Critical Active Biotech AB
Publication of AU2020408179A1 publication Critical patent/AU2020408179A1/en
Application granted granted Critical
Publication of AU2020408179B2 publication Critical patent/AU2020408179B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2020408179A 2019-12-19 2020-12-18 Compounds for treatment of eye diseases associated with excessive vascularisation Active AU2020408179B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP19218062 2019-12-19
EP19218062.8 2019-12-19
EP20156158.6 2020-02-07
EP20156158 2020-02-07
PCT/EP2020/086993 WO2021123142A1 (en) 2019-12-19 2020-12-18 Compounds for treatment of eye diseases associated with excessive vascularisation

Publications (2)

Publication Number Publication Date
AU2020408179A1 AU2020408179A1 (en) 2022-06-30
AU2020408179B2 true AU2020408179B2 (en) 2025-04-10

Family

ID=74141502

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020408179A Active AU2020408179B2 (en) 2019-12-19 2020-12-18 Compounds for treatment of eye diseases associated with excessive vascularisation

Country Status (14)

Country Link
US (2) US11478465B2 (cg-RX-API-DMAC7.html)
EP (2) EP3886858B1 (cg-RX-API-DMAC7.html)
JP (1) JP7730816B2 (cg-RX-API-DMAC7.html)
CN (1) CN114845718B (cg-RX-API-DMAC7.html)
AU (1) AU2020408179B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022009192A2 (cg-RX-API-DMAC7.html)
CA (1) CA3157394A1 (cg-RX-API-DMAC7.html)
DK (1) DK3886858T3 (cg-RX-API-DMAC7.html)
ES (1) ES2921360T3 (cg-RX-API-DMAC7.html)
IL (1) IL293469B2 (cg-RX-API-DMAC7.html)
MX (1) MX2022006439A (cg-RX-API-DMAC7.html)
PL (1) PL3886858T3 (cg-RX-API-DMAC7.html)
WO (1) WO2021123142A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202204939B (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20240329A1 (es) 2019-06-05 2024-02-27 Regeneron Pharma Dispositivos y metodos para administracion de dosis de precision
CA3157394A1 (en) * 2019-12-19 2021-06-24 Helena ERIKSSON Compounds for treatment of eye diseases associated with excessive vascularisation
AU2022248724A1 (en) 2021-04-01 2023-11-02 Active Biotech Ab Laquinimod formulation for ocular use
US12649031B2 (en) 2021-09-08 2026-06-09 Regeneron Pharmaceuticals, Inc. Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
EP4734995A1 (en) * 2023-06-28 2026-05-06 Board of Regents, The University of Texas System Quinoline carboxamides for use in the treatment of mpn
CN117256554A (zh) * 2023-09-08 2023-12-22 益诺思生物技术南通有限公司 一种c57bl/6j小鼠新生血管型眼病模型及其构建方法
KR102925647B1 (ko) * 2023-10-13 2026-02-11 재단법인 대구경북첨단의료산업진흥재단 안질환 치료제

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2537517A1 (en) * 2011-06-22 2012-12-26 Active Biotech AB Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide
US20190015521A1 (en) * 2017-07-17 2019-01-17 Macregen, Inc. Topical delivery of therapeutic agents using cell-penetrating peptides for the treatment of age-related macular degeneration and other eye diseases

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077851A (en) 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
SE9801474D0 (sv) * 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
US6875869B2 (en) 2002-06-12 2005-04-05 Active Biotech Ab Process for the manufacture of quinoline derivatives
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
WO2008124828A1 (en) * 2007-04-10 2008-10-16 Myriad Genetics, Inc. Methods for treating vascular disruption disorders
WO2010070449A2 (en) 2008-12-17 2010-06-24 Actavis Group Ptc Ehf Highly pure laquinimod or a pharmaceutically acceptable salt thereof
AU2011274496B2 (en) * 2010-07-09 2016-03-10 Teva Pharmaceutical Industries Ltd. Deuterated N-ethyl-N-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof
EP2463289A1 (en) 2010-11-26 2012-06-13 Almirall, S.A. Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
EP2527344A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
SG10201606191PA (en) 2011-07-28 2016-09-29 Teva Pharma Treatment of multiple sclerosis with combination of laquinimod and glatiramer acetate
EP2844268A4 (en) * 2012-04-20 2015-11-25 Univ Howard METHOD FOR THE TREATMENT OF EYE DISEASE AND COMPOSITIONS FOR THE TREATMENT OF EYE DISEASE
WO2013173307A1 (en) * 2012-05-16 2013-11-21 Neil Desai Multi-target modulation for treating fibrosis and inflammatory conditions
TW201400117A (zh) * 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
AU2013342275B2 (en) * 2012-11-08 2017-11-09 Clearside Biomedical, Inc. Methods and devices for the treatment of ocular diseases in human subjects
CN105163730B (zh) * 2013-01-08 2018-10-30 帕萨罗杰卡有限公司 用于治疗脱髓鞘疾病的方法和组合物
BR112016000177A2 (pt) * 2013-07-11 2017-12-12 Novartis Ag usos de um antagonista do vegf no tratamento de doenças neovasculares coriorretinianas e de permeabilidade em pacientes pediátricos, seringa pré-cheia, kit e formulação de liberação lenta
WO2015060812A1 (en) 2013-10-21 2015-04-30 Howard University Treating ocular disease with efflux transporter inhibitors
WO2015073697A1 (en) * 2013-11-15 2015-05-21 Teva Pharmaceutical Industries Ltd. Treatment of glaucoma using laquinimod
EP3082761A2 (en) * 2013-12-20 2016-10-26 Emory University Formulations and methods for targeted ocular delivery of therapeutic agents
WO2017120355A1 (en) 2016-01-06 2017-07-13 Teva Pharmaceutical Industries Ltd. Dihydroquinolines and uses thereof
CN108778330A (zh) * 2016-01-08 2018-11-09 科尼尔赛德生物医学公司 用阿柏西普和其他生物制品治疗后眼部障碍的方法和装置
MA51327A (fr) 2017-12-22 2021-05-26 Chemocentryx Inc Composés cycliques fusionnés en 5,5 à substitution diaryle, utilisés en tant qu'inhibiteurs du c5ar
MX2020006459A (es) 2017-12-22 2020-11-06 Chemocentryx Inc Compuestos de anillos fusionados 6,5 diaril sustituidos como inhibidores de c5ar.
ES2993034T3 (en) 2018-04-02 2024-12-20 Chemocentryx Inc Prodrugs of fused-bicyclic c5ar antagonists
CA3157394A1 (en) * 2019-12-19 2021-06-24 Helena ERIKSSON Compounds for treatment of eye diseases associated with excessive vascularisation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2537517A1 (en) * 2011-06-22 2012-12-26 Active Biotech AB Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide
US20190015521A1 (en) * 2017-07-17 2019-01-17 Macregen, Inc. Topical delivery of therapeutic agents using cell-penetrating peptides for the treatment of age-related macular degeneration and other eye diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ABDEL-RAHMAN M H ET AL: EXPERIMENTAL EYE RESEARCH, ACADEMIC PRESS LTD, LONDON, vol. 91, no. 6, 1 December 2010 (2010-12-01), pages 837 - 843, XP027527920, ISSN: 0014-4835, [retrieved on 20101103] *

Also Published As

Publication number Publication date
US12208091B2 (en) 2025-01-28
MX2022006439A (es) 2022-07-19
US20230066364A1 (en) 2023-03-02
ZA202204939B (en) 2023-12-20
IL293469A (en) 2022-08-01
ES2921360T3 (es) 2022-08-24
WO2021123142A1 (en) 2021-06-24
IL293469B1 (en) 2023-12-01
CN114845718B (zh) 2025-05-16
DK3886858T3 (da) 2022-08-22
PL3886858T3 (pl) 2022-08-29
IL293469B2 (en) 2024-04-01
JP2023509336A (ja) 2023-03-08
EP3886858A1 (en) 2021-10-06
EP4094765A1 (en) 2022-11-30
CA3157394A1 (en) 2021-06-24
EP3886858B1 (en) 2022-05-11
US11478465B2 (en) 2022-10-25
BR112022009192A2 (pt) 2022-07-26
AU2020408179A1 (en) 2022-06-30
CN114845718A (zh) 2022-08-02
US20210322400A1 (en) 2021-10-21
JP7730816B2 (ja) 2025-08-28
KR20220118419A (ko) 2022-08-25

Similar Documents

Publication Publication Date Title
US12208091B2 (en) Compounds for treatment of eye diseases associated with excessive vascularisation
AU2023251388B2 (en) Treatment of ophthalmic conditions such as macular degeneration, glaucoma, and diabetic retinopathy using pharmaceutical agents that eliminate senescent cells
RU2676274C2 (ru) Применение антагониста vegf при лечении хориоретинальных неоваскулярных нарушений и нарушений проницаемости у педиатрических пациентов
RS62827B1 (sr) Tretman staračke degeneracije žute mrlje koja ima malu aktivnu leziju neovaskularizacije sudovnjače
KR102307421B1 (ko) 다중 키나아제 억제제 및 안구 섬유증에의 사용
US20250134881A1 (en) Treatment of ocular inflammatory diseases using laquinimod
Van Bergen et al. Complementary effects of bevacizumab and MMC in the improvement of surgical outcome after glaucoma filtration surgery
TW200815416A (en) Compositions and methods for treating, reducing, ameliorating, or alleviating posterior-segment ophthalmic diseases
Kuerten et al. Transplantation of PEDF-transfected pigment epithelial cells inhibits corneal neovascularization in a rabbit model
CN105555364A (zh) 炎症性眼科疾病的局部治疗
Galor et al. Phase I study of subconjunctival ranibizumab in patients with primary pterygium undergoing pterygium surgery
JP6835836B2 (ja) 脈絡膜血管新生の処置のための方法及び医薬組成物
Van Bergen et al. Integrin α5β1 inhibition by CLT-28643 reduces postoperative wound healing in a mouse model of glaucoma filtration surgery
HK40061312A (en) Compounds for treatment of eye diseases associated with excessive vascularisation
HK40061312B (en) Compounds for treatment of eye diseases associated with excessive vascularisation
EA045318B1 (ru) Соединения для лечения глазных болезней, связанных с избыточной васкуляризацией
Doganay et al. Evaluation of the effects of resveratrol and bevacizumab on experimental corneal alkali burn
WO2020203822A1 (ja) 血管新生を伴う網膜疾患の治療又は予防のための併用医薬
WO2025116819A1 (en) Methods of treating neovascular eye diseases
EA043539B1 (ru) Фармацевтическая комбинация и ее применение в способе лечения офтальмологических заболеваний
Ferrer et al. Ophthalmic therapeutics: new basic research and clinical studies

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)